

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10540276
	Filing Date		2005-06-21
	First Named Inventor		Ana Ingrid Kristina Berggren
	Art Unit		1626
	Examiner Name		Shawquia Young
	Attorney Docket Number		133087.10001 100939-1P US

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5100591		1992-03-31	Cerfontaine et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0377457	EP		1990-07-11	Fujisawa Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	2	1205478	EP		2002-05-15	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	3	0046209	WO		2000-08-10	Sanofi-Synthelabo		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10540276		
		Filing Date		2005-06-21		
		First Named Inventor		Ana Ingrid Kristina Berggren		
		Art Unit		1626		
		Examiner Name		Shawquia Young		
		Attorney Docket Number		133087.10001 100939-1P US		

	4	03078413	WO		2003-09-25	Solvay Pharmaceuticals B.V.		<input type="checkbox"/>
	5	2736230	DE		1978-02-16	Nippon Soda Co., Ltd.		<input type="checkbox"/>
	6	458361	CH		1968-08-30	Eprova Ltd.		<input type="checkbox"/>
	7	0397859	EP		1990-11-22	Terumo Kabushiki Kaisha		<input type="checkbox"/>
	8	0656354	EP		1995-06-07	Sanofi		<input type="checkbox"/>
	9	9202513	WO		1992-02-20	Fujisawa Pharmaceutical Co. Ltd.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Al-Dabbagh et al., "Species differences in oxidative drug metabolism: some basic considerations," Archives of toxicology, Supplement Archiv fur Toxikologie. (1984) supplement 7:219-231.	<input type="checkbox"/>
	2	Bundgaard, Design of Prodrugs, page 1 (1985) Elsevier Science Publishers.	<input type="checkbox"/>
	3	Pertwee "Pharmacology of cannabinoid receptor ligands," Current Medicinal Chemistry (1999) 6(8):635-664.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10540276
	Filing Date	2005-06-21
	First Named Inventor	Ana Ingrid Kristina Berggren
	Art Unit	1626
	Examiner Name	Shawquia Young
	Attorney Docket Number	133087.10001 100939-1P US

	4	Silverman, The Organic Chemistry of Drug Design and Drug Action (1992) Academic Press, Inc. pp. 356-400.	<input type="checkbox"/>
	5	Vippagunta et al., "Crystalline Solids," Advanced Drug Delivery Reviews (2001) 48:3-26.	<input type="checkbox"/>
	6	Welin-Berger et al., "Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase," International Journal of Pharmaceutics (2000) 200(2):249-260.	<input type="checkbox"/>
	7	Boon et al., "Pteridines V. Derivatives of 1,4-dihydro-1- and 3,4-dihydro-3-methyl-6,7-diphenylpteridine," Journal of the Chemical Society (1957) pp. 2159-2161.	<input type="checkbox"/>
	8	Brittain "X-Ray Powder Diffraction of Pharmaceutical Materials," American Pharmaceutical Review (2002) 5(1)74-80.	<input type="checkbox"/>
	9	Di Marzo et al., "Leptin-regulated endocannabinoids are involved in maintaining food intake," Nature (2001) 410:822-825.	<input type="checkbox"/>
	10	Gavezzotti "Are Chrystal Structures Predictable?" Acc Chem Res (1994) 27:309-314.	<input type="checkbox"/>
	11	Howlett et al., "Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction," Journal of Neurochemistry (2000) 74(5):2174-2181.	<input type="checkbox"/>
	12	Martin ""Frozen" Transition States Pentavalent Carbon et al.," Science (1983) 221(4610):509-514.	<input type="checkbox"/>
	13	Taylor et al., "Pteridines. X. A New Approach to the Synthesis of Pteridines," J Am Chem Soc (1953) 75 (8):1904-1908.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10540276
	Filing Date	2005-06-21
	First Named Inventor	Ana Ingrid Kristina Berggren
	Art Unit	1626
	Examiner Name	Shawquia Young
	Attorney Docket Number	133087.10001 100939-1P US

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.